New Agent and Innovative Therapies Program (NAIT) September newsletter available now


  • ADVL1412 (nivolumab/ipilimumab) is being amended to reopen for patients with Ewing sarcoma and rhabdomyosarcoma. Patients should have available archival tissue but are not required to demonstrate PDL1 expression for enrollment.

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email:

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.